CXCL12/CXCR4 facilitates perineural invasion via induction of the Twist/S100A4 axis in salivary adenoid cystic carcinoma

The activation of CXCL12/CXCR4 axis participated in the progression of multiple cancers, but potential effect in terms of perineural invasion (PNI) in SACC remained ambiguous. In this study, we identified that CXCL12 substantially expressed in nerve cells. CXCR4 strikingly expressed in tumour cells, and CXCR4 expression was closely associated with the level of EMT-associated proteins and Schwann cell hallmarks at nerve invasion frontier in SACC. Activation of CXCL12/CXCR4 axis could promote PNI and up-regulate relative genes of EMT and Schwann cell hallmarks both in vitro and in vivo, which could be inhibited by Twist silence. After overexpressing S100A4, the impaired PNI ability of SACC cells induced by Twist knockdown was significantly reversed, and pseudo foot was visualized frequently. Collectively, the results indicated that CXCL12/CXCR4 might promote PNI by provoking the tumour cell to differentiate towards Schwann-like cell through Twist/S100A4 axis in SACC.     

Development of health biotechnology in developing countries: Can private-sector players be the prime movers?

Health biotechnology has rapidly become vital in helping healthcare systems meet the needs of the poor in developing countries. This key industry also generates revenue and creates employment opportunities in these countries. To successfully develop biotechnology industries in developing nations, it is critical to understand and improve the system of health innovation, as well as the role of each innovative sector and the linkages between the sectors. Countries' science and technology capacities can be strengthened only if there are non-linear linkages and strong interrelations among players throughout the innovation process; these relationships generate and transfer knowledge related to commercialization of the innovative health products. The private sector is one of the main actors in healthcare innovation, contributing significantly to the development of health biotechnology via knowledge, expertise, resources and relationships to translate basic research and development into new commercial products and innovative processes. The role of the private sector has been increasingly recognized and emphasized by governments, agencies and international organizations. Many partnerships between the public and private sector have been established to leverage the potential of the private sector to produce more affordable healthcare products. Several developing countries that have been actively involved in health biotechnology are becoming the main players in this industry. The aim of this paper is to discuss the role of the private sector in health biotechnology development and to study its impact on health and economic growth through case studies in South Korea, India and Brazil. The paper also discussed the approaches by which the private sector can improve the health and economic status of the poor.     

替雷利珠单抗注射液联合白蛋白紫杉醇和卡铂对晚期NSCLC患者肠道菌群和SII、PNI的影响

摘要 目的：探讨替雷利珠单抗注射液联合白蛋白紫杉醇和卡铂对晚期非小细胞肺癌（NSCLC）患者肠道菌群和预后营养指数（PNI）、全身免疫炎症指数（SII）的影响。方法：选取2020年5月~2023年2月期间在南京市江宁医院及东南大学附属中大医院接受治疗的晚期NSCLC患者115例。根据随机数字表法将患者分为对照组和研究组,各为57例和58例。对照组接受白蛋白紫杉醇和卡铂治疗,研究组在对照组基础上接受替雷利珠单抗注射液治疗。对比两组客观缓解率（ORR）、疾病控制率（DCR）、血清肿瘤标志物[细胞角蛋白19片段（CYFRA21-1）、癌胚抗原（CEA）、糖类抗原125（CA125）]、肠道菌群（双歧杆菌、乳酸杆菌、肠球菌）和SII、PNI,同时观察两组治疗期间不良反应发生情况。结果：研究组ORR（44.83%）、DCR（77.59%）均高于对照组的24.56%、50.88%（P<0.05）。与对照组治疗后相比,研究组CYFRA21-1、CEA、CA125、肠球菌、SII更低,双歧杆菌、乳酸杆菌、PNI更高（P<0.05）。两组不良反应发生率对比未见差异（P>0.05）。结论：替雷利珠单抗注射液联合白蛋白紫杉醇和卡铂治疗晚期NSCLC患者,可提升临床疗效,改善SII、PNI和肠道菌群。     

神经生长因子通过抑制内质网应激促进外周神经损伤后髓鞘碎片的清除

神经生长因子 (never growth factor,NGF）可促进损伤外周神经的修复并加速轴突和髓鞘的再生,但对外周神经损伤前期作用的研究报道较少。本研究主要探究在损伤外周神经前期,NGF能否加速施旺细胞 (Schwann cells, SCs) 对髓鞘碎片的清除及其调控机制。将坐骨神经损伤的Wistar雄性大鼠连续5 d给予NGF治疗,并运用分子生物学检测手段分析损伤坐骨神经内部髓鞘碎片的清除,细胞的凋亡及内质网应激 (endoplasmic reticulum stress, ERS) 的表达和变化。免疫荧光分析结果显示,与模型组相比,NGF给药组显著加速髓鞘碎片的清除,并促进SCs的增殖 (46.33 ± 5.68 vs. 66.69 ± 8.76, P＜ 0.05 for MPZ; 47.58 ± 4.52 vs. 37.69 ± 2.50, P＜ 0.01 for GFAP)。TUNEL免疫组化证实,NGF可有效抑制SCs的凋亡(25 ± 4 vs. 37 ± 6, P＜ 0.05),Western印迹结果显示,模型组坐骨神经内部内质网应激水平被过度激活,给予NGF治疗后,相关蛋白质表达被逆转 (1.03 ± 0.03 vs. 1.24 ± 0.07, P＜ 0.01 for PDI; 1.16 ± 0.16 vs. 1.48 ± 0.10, P＜ 0.05 for GRP-78; 1.33 ± 0.11 vs. 1.76 ± 0.17, P＜ 0.01 for Caspase-12; 1.01 ± 0.05 vs. 1.39 ± 0.16, P＜ 0.01 for CHOP)。上述结果证实,NGF可通过抑制内质网应激减少神经组织内细胞的凋亡,并加速髓鞘碎片的清除,促进外周神经损伤的修复。